infliximab

Ligand id: 5004

Name: infliximab

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: infliximab

View interactive charts of activity data from GtoPdb and ChEMBL (where available) across species

Bioactivity Comments
Infliximab has been reported to induce an anti-chimeric antibody response in almost 15% of Crohn's disease patients (47 tested) [5]. This indicates that as predicited, humans can mount an immune response to whole murine variable domains, and is the underlying rationale promoting the development of clinical antibodies with variable domains with more human character (i.e. humanised or fully human monoclonal developments).
Selectivity at ligand targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Affinity Units Concentration range (M) Reference
tumour necrosis factor shed form Hs Antibody Binding 8.7 pKd - 4
pKd 8.7 (Kd 1.8x10-9 M) [4]
Description: Binding affinity of antibody cA2 to recombinant human TNFα